As the prevalence of Parkinson’s disease rises worldwide, researchers are questioning whether targeted supplements can impact inflammation, oxidative stress, mitochondria, and the gut microbiome, but current evidence remains promising, controversial, and far from conclusive.
Review: Dietary Supplements for Parkinson’s Disease: Current State of the Science. Image credit: Peterschreiber.media / Shutterstock
In a recent review published in Parkinson’s disease journalour group evaluated the disease-modifying potential of nutritional supplements in Parkinson’s disease through evidence from human clinical trials. This review focused on clinical outcomes and biomarker-based evidence as surrogate measures of disease modification, rather than conclusive evidence to supplement slowing disease progression.
background
Parkinson’s disease is the world’s fastest growing neurological disease, with prevalence predicted to double by 2050. Although drugs like levodopa are effective in controlling symptoms, they do not prevent the continued loss of dopamine-producing brain cells that contribute to the progression of Parkinson’s disease.
Research has also investigated how nutrients reduce inflammation, oxidative stress, mitochondrial dysfunction, and changes in the gut microbiome associated with neurodegeneration. Despite limited clinical evidence, many people with Parkinson’s disease already use supplements regularly. Further research is needed to determine which supplements truly slow disease progression.
The main mechanisms by which omega-3 fatty acids (N-3), nicotinamide riboside, and biotics influence important pathophysiological features of Parkinson’s disease. Inflammation, oxidative stress, and mitochondrial dysfunction are interrelated central features that interact bidirectionally with α-synuclein aggregation. N-3 and NR may reduce inflammation, oxidative stress, and mitochondrial dysfunction, while biotics modulate the gut microbiota and affect α-synuclein aggregation and downstream pathways. Pathophysiological features: A, neuroinflammation and oxidative stress. B, mitochondrial dysfunction. C, aggregation of α-synuclein. D, dysbiosis of intestinal flora. Interventions: 1, n-3; 2, NR; 3, biotics.
Why are nutritional supplements important?
Parkinson’s disease affects sleep, digestion, mood, thinking, and movement. This degenerative disease is caused by the loss of dopamine-producing nerve cells and the accumulation of alpha-synuclein, a toxic protein clump, in the brain. This is associated with factors such as chronic inflammation, oxidative stress, mitochondrial dysfunction, and changes in the gut microbiome. Nutraceuticals are becoming increasingly popular because many of them have antioxidant and anti-inflammatory properties.
Omega-3 fatty acids show early promise
Omega-3 fatty acids are widely known for supporting heart health, but research suggests they may also protect brain cells. Several clinical trials reported reductions in inflammatory markers and improved antioxidant defenses as a result of omega-3 supplementation. In some studies, patients also showed improved scores on the Unified Parkinson’s Disease Rating Scale.
However, studies have shown inconsistent results, as omega-3 fatty acids have also shown benefits in other trials when combined with vitamin E and other nutrients. Despite the limitations of these studies, researchers argue that omega-3 fatty acids hold promise because they target multiple pathways involved in disease development, including oxidative stress and inflammation.
B vitamins and nicotinamide riboside
Vitamin B is essential for energy production and cellular metabolism. Nicotinamide riboside, a form of vitamin B3, is commonly used to maintain mitochondrial function. Mitochondria, the power source of cells, are thought to play a role in the progression of Parkinson’s disease.
Although clinical studies have shown that high doses of nicotinamide riboside may improve MDS-UPDRS scores, especially motor scores, other trials have not shown clear clinical efficacy and disease improvement has not yet been demonstrated. The researchers noted that differences in dosage could explain these conflicting findings. Studies using higher doses appeared to be more successful than those using lower doses.
Although the evidence remains limited, ongoing large-scale clinical trials may soon reveal whether nicotinamide riboside can indeed slow disease progression. If successful, this supplement could be useful in future Parkinson’s disease management strategies.
Vitamin D and Vitamin E have different results
Vitamin D is known to play a role in bone health, but it can also affect brain function and inflammation. Although one trial reported an improvement in Hoehne and Jarl stages after vitamin D supplementation, there was no difference in UPDRS total score, and other studies have not shown consistent disease-modifying effects. Variability between studies may be due to differences in doses used, body mass index (BMI), and duration of study conduct.
Vitamin E can theoretically reduce oxidative damage, but studies have not demonstrated that it significantly improves disease progression when used alone. Subsequent trials primarily tested vitamin E in combination with omega-3 fatty acids rather than as a sole treatment.
Creatine, Coenzyme Q10, Curcumin
Some supplements that once showed great promise have yielded inconsistent or negative results in human studies. Creatine was hypothesized to support cellular energy and slow the progression of Parkinson’s disease, but large long-term trials showed no disease-modifying effects.
Coenzyme Q10 is also a compound that supports mitochondrial function and has been shown to reduce the progression of Parkinson’s disease in small clinical studies, but not in large studies. The review also notes that coenzyme Q10 has been classified by major clinical guidance bodies as ineffective in slowing the progression of Parkinson’s disease.
Curcumin, the main component of the spice turmeric, is said to have anti-inflammatory properties. However, to date, there is only one small human pilot study evaluating curcumin on Parkinson’s disease progression, which did not show significant improvements in MDS-UPDRS scores or total Hoehn and Yahr scores. Therefore, curcumin is not considered effective.
Gut microbiome and biotics
One of the most interesting areas of Parkinson’s disease research concerns the gut microbiome. Many patients experience gastrointestinal problems years before motor symptoms appear, suggesting that the intestines may be involved in pathways involved in the development of the disease. Research has shown that people with Parkinson’s disease often have fewer beneficial bacteria that produce short-chain fatty acids.
Some studies have shown that probiotics reduce inflammation, improve antioxidant activity, and even reduce symptom severity scores. In general, there is evidence that multi-strain probiotics may be more beneficial than single-strain probiotic preparations. This is probably because different bacteria perform complementary functions. Early studies suggest that some probiotic, prebiotic, and synbiotic interventions may impact the intestinal barrier, inflammatory markers, oxidative stress markers, and even microbiome markers, but the evidence remains heterogeneous and limited, particularly with respect to prebiotics.
Future direction of nutritional research
The researchers stressed that no nutritional supplements have yet been proven to halt the progression of Parkinson’s disease. However, there is still potential for some nutritional supplements, such as combinations of omega-3 fatty acids and vitamin E, nicotinamide riboside, and biologicals.
Future studies should use larger populations, longer follow-up periods, and more accurate biomarkers to determine whether these interventions truly alter disease progression rather than merely temporarily improving symptoms. Additionally, the authors suggest that studies may need to test holistic approaches, potentially combining nutritional supplements with broader lifestyle interventions such as diet and exercise.
conclusion
Nutraceuticals are increasingly being investigated as a supportive strategy that may help modify pathways associated with Parkinson’s disease progression.
Recent studies suggest that the combination of biotics, nicotinamide riboside, omega-3 fatty acids, and vitamin E may modulate inflammation, oxidative stress, mitochondrial dysfunction, and gut microbiome health associated with neurodegenerative diseases. However, findings remain inconsistent, and many supplements, including creatine and coenzyme Q10, have failed to demonstrate reliable long-term effects in large clinical trials.
The researchers concluded that nutritional supplements should not replace standard medical care, but may complement future treatment strategies. Larger, longer and methodologically stronger studies are needed before definitive clinical recommendations can be made.
Click here to download your PDF copy.
Reference magazines:
- Prasad, A., Schuller, M. S., Flanagan, R., Dayal, V., and Lysander, F. E. (2026). Dietary supplements for Parkinson’s disease: current state of the science. Journal of Parkinson’s Disease. Doi: 10.1177/1877718X261446386, https://journals.sagepub.com/doi/epub/10.1177/1877718X261446386
